STOCK TITAN

Bio Essence raises board limit from 3 to 10 directors

Holders of 63.92% of Bio Essence's issued and outstanding common stock signed the written consent covering the board amendment and director elections.

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
8-K

Rhea-AI Filing Summary

Bio Essence Corp. (BIOE) reports that shareholders elected Xiying (Thea) Zhang and Geoff Fellows as directors effective October 19, 2026. Shareholders also amended the bylaws, raising the permitted maximum from three directors to ten while retaining a minimum of one. Holders of 63.92% of issued and outstanding common stock signed the written consent. Zhang has more than 15 years of experience in operations, manufacturing strategy and product commercialization; Fellows is chief executive officer of Embarcadero Accessible Multi-Family Office and has more than three decades of experience in finance, operations, compliance and governance.

Filing Explained

The amended bylaws set a range of one to ten directors, but allow a shareholder majority to override that limit by meeting or written consent, so ten is not an unconditional ceiling.

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year Governance
The company amended its charter documents, bylaws, or changed its fiscal year.
Prior maximum board size 3 directors Prior bylaw limit
Amended maximum board size 10 directors Amended bylaw limit
Minimum board size 1 director Amended bylaw limit
Shareholder consent 63.92% Issued and outstanding common stock held by consenting shareholders
Zhang experience More than 15 years Operations, manufacturing strategy and product commercialization
Fellows experience More than three decades Finance, operations, compliance and governance
authorized number of Directors regulatory
"The authorized number of Directors shall be no less than One"
issued and outstanding shares financial
"63.92% of the issued and outstanding shares of common stock"
The total number of shares a company has issued and that are currently held by investors, excluding any shares the company has bought back and kept in its treasury. Investors use this count like the number of slices in a pie to calculate market value per share, ownership percentages and per-share metrics such as earnings per share, so it directly affects how the company’s value and each shareholder’s stake are measured.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many directors can Bio Essence Corp. have under its amended bylaws?

Bio Essence Corp.'s bylaws authorize no fewer than one and no greater than ten directors. The amendment changed the prior permitted range of one to three directors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
false --12-31 0001723059 0001723059 2026-10-15 2026-10-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 8-K

 

Current Report

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

October 15, 2026

(Date of Report)

 

BIO ESSENCE CORP.

(EXACT NAME OF REGISTRANT AS SPECIFIED IN CHARTER)

 

California   000-56263   94-3349551

(STATE OR OTHER JURISDICTION OF

INCORPORATION OR ORGANIZATION)

  (COMMISSION FILE NO.)   (IRS EMPLOYEE
IDENTIFICATION NO.)

 

2955 Main Street, Suite 300, Irvine, CA 92618
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)

 

(949) 706-9966
(ISSUER TELEPHONE NUMBER)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
N/A   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter. ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensation Arrangements of Certain Officers

 

On October 19, 2026, a majority of shareholders of Bio Essence Corp., a California corporation (“Company”) elected by way of written consent Thea Zhang and Geoff Fellows as a Directors of the Company.

 

Ms. Zhang is a strategic business and operations leader with more than fifteen years of experience overseeing business operations, manufacturing strategy, and product commercialization. She previously worked for Spyglass Pharma, Inc., as a Senior Manager, and Oasis Medical, Inc., in the same role. Ms. Zhang received a Master’s Degree in Business Administration from the University of Toledo, and a Bachelor’s Degree in Engineering – Pharmaceutical Science from Nanjing University of Technology in Nanjing, China.

 

Mr. Fellows similarly has experience as a business leader, with years of experience in the industry. He is the chief executive officer of Embarcadero Accessible Multi-Family Office, where he has historically overseen the firm’s tax and legal departments. Mr. Fellows brings more than three decades of experience in finance, operations, compliance, and governance from across the financial services industry to the Board.

 

Ms. Zhang and Mr. Fellows have no arrangement or understanding regarding their appointment, nor are they a party to any material plan, contract, or arrangement, and no transactions disclosable pursuant to Item 404(a) of Regulation S-K.

 

Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change of Fiscal Year

 

On October 19, 2026, a majority of shareholders of the Company voted to modify the Bylaws of the Company to remove the limit on the number of Directors that could be elected to the Board of Directors. Under the original Bylaws, the Company could have between one and three Directors. The new Amendment, memorialized in the Consent attached here, changes the limit from three Directors to ten directors. No other revisions were made to the Bylaws.

 

1

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIO ESSENCE CORP.
   
  /s/ Yin Yan
  By: Yin Yan
  Its: Chief Executive Officer
  Dated: October 23, 2026

 

 

2

 

Exhibit 99.1

 

CONSENT OF SHAREHOLDERS IN LIEU OF MEETING (BIO ESSENCE, CORP.) Th e undersignecl shai eholdel s, holding 63 . 92 % of the issued and outstanding shares of’ common stock in Bio Essence, Coi p . , a California corporation (the Colitis/iJ›”) entitled to vote on the present matter, hereby consents in lieu of a meeting pursuant to A i ticle 1 V Section 6 of the Company's Bylaws anal Cal ifol nia Coi'porations Code t 603 (a) as follows : WHEREAS, the Company's Board of“ Dir ectors has historically inclu‹Jed live ( 5 ) total directors, elected by a iiiajoi ity of shareholders alter nomination by the Board of Dir ectors ; WHEREAS . the Company’s clii i ent Boar - d of Dir ectors incl udes tlii ee ( 3 ) inclivid uals, and the Board of Directors has vetted and sought to appoint a forii‘th and hftli member, as discussed below ; WHEREAS, Article II, Section 4 of the Cornpan)•’s Bylaws contain a line it on the number of director s that may be apJsointed, which a iiiajority of the shareholJei s over iode dcii trip prior election cycles. WHEREA S. the tindersi s ned sliareholdei s, who collectively own a majority of the issued and outstanding corrlrnon stock in the Coliapany, agi‘ee to foi'iiially reiiiove the Iimitation iiiiJaosed by Alticle 11, Section 4 ; W HEREA S . the Boar d of Directors have none inated Xiying ( 4 “hea) Zhang to I e aJapointed as a Dir ector of the Company, and havin 3 reviewed Ms . Zhang’s qtialiilcations . the undersi s ned shai eliolders apJarove of, and elect, Els . Zhang to the Board of Dir ectors of the Coin pany ; WHEREAS, the Board of Directors have nom treated Geoff Fellows to be aJapointed as a Dii‘ector of the Cont |aany, and having ieviewed Mr . Fellows’s qualifications, the unclersigned shareholders approve of, and elect . Mr . Fellows to the Board of Dii ectoi‘s of the Company ; NOW TH EREFORE, the undersigned shareholders consent as follows : RESOLVED that, Article 11 . Section 4 of the Company’s Bylaws are hereby amended to include the language below, which supersedes the original section in its entirety : Section 4. N UM BER AND Q UAL I F ICATION OF DI RECTORS. The atithoi - ized number of Dil'ectors shall be no less than One ( 1 ) anal no greater than Tell ( 10 ), unless consenterl to lay a majority of the Slaarelioldei s tlr‘origh an annual ineetilig, sJaecial meeting, or consent - in - 1 ten of meeting .

 

 

 

RESOLVED, that Xiying (Thea) Zhang is appointed as a Director of the Company effective October 19, 2026. RESOLVED, that Geoff Fellows is a n inted as a Director of the CoinJaany effective October 19. 2026. RESOLVED, that all prior acts of the CornJaany's Officers and Boai d of Directol's are cleemed to have been in the best interest of’ the Company. Dated: October 19. 2026 By: Yin You Its: Shai elJolcter ( I 3,39d,000 Shai es) Dy: JiaiJ Yang Its: S hareholdei' (21,000,000 Shares)

Exhibit 99.2

 

1 Acceptance of Election to the Board of Directors of BIO ESSENCE CORP. The undersigned, having been nominated by tire Board of Directors of Bio Essence Corp. (the ‘Company” for election to the same, and having been elected by a majority of the shareholders of the Company to the Board of Directors, hereby accepts my election and appointment as Director of the Company. Xiying Zhang Dated: October 19, 2026

Exhibit 99.3

 

Acceptanc ‹ of Elecli ‹ n i o t h c li‹ arm o I i Directors of BIO Ut fiI‘. N£ 1' C OR1’. The undersigned, laavingc i een noiiii nate 1 i ic Bt iii r1 o1 Directors ot Bio Essence Corp. of the Company to the Boarcl oi I i iect‹›i s. I ‹ , ’ ' na; c ction and appointment as Director of the Company. Off Fellows Dated: October , 2020

Filing Exhibits & Attachments

6 documents

Keep reading